Biomatter Raises $18M Series A to Scale Its AI-Powered Enzyme Design for Global Industry Leaders
8 Articles
8 Articles
Lithuania’s Biomatter raises $18M for AI enzyme design and a US push
Vilnius-based Biomatter has raised $18M in a Series A round to scale its AI enzyme design platform. Astanor led the oversubscribed round. Existing investors UVC Partners, Inventure and Metaplanet also took part. The company announced the round in a press release distributed by Business Wire on 12 November. It did not disclose a valuation. TNW […] This story continues at The Next Web
Hastings Tribune
HealthTech HotSpotBiomatter Raises $18M Series A to Scale Its AI-Powered Enzyme Design for Global Industry Leaders
VILNIUS, Lithuania--(BUSINESS WIRE)--Nov 12, 2026-
Biomatter, a biotechnology startup that has been operating since 2018, has received its largest investment to date – 18 million US dollars. According to its CEO and one of the founders, Laurynas Karpus, the Lithuanian company is today among the leading organizations in the world that create new enzymes, sometimes performing functions that do not even exist in nature. “We are expanding the horizon of what is possible,” L. Karpus tells LRT.lt.
BizToc
Tech.euBiomatter lands $18M to speed up enzyme development with AI
Biomatter, a company specialising in custom enzyme design, has raised $18 million in an oversubscribed Series A funding round led by Astanor, with participation from existing investors UVC Partners, Inventure and Metaplanet. Biomatter develops computational technology to design enzymes tailored to…
Biomatter Raises $18M Series A to Scale Its AI-Powered Enzyme Design ...
Biomatter, a biotechnology startup that uses artificial intelligence (AI) to create new enzymes that do not exist in nature, has raised $18 million (about €16.2 million) from investors in a Series A round of funding. The funds will be used to establish a new center in Vilnius, expand the company's sales team, and expand its operations in the US.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
